ACNP: Novel NMDA Receptor Modulator Significantly Reduces Depression Scores Within Hours
Naurex reports Phase 2 data at ACNP showing a single administration of novel NMDA receptor modulator GLYX-13 produced statistically significant reductions in depression scores within 24 hours in subjects who had failed prior treatment. The effect size, a measure of efficacy, observed at 24 hours and seven days, was nearly double that seen with other antidepressants after weeks of repeated dosing ... Read News
Phase II Data Presented At ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within ...
HOLLYWOOD, Fla. and EVANSTON, Ill., Dec. 6, 2012 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported ... Read News
Mental Health: A Report Of The Surgeon General - Chapter 3
Aims and methodological problems in multimodal treatment studies. Canadian Journal of Psychiatry, 38, 458–464. Journal of Clinical and Child Psychology, 19, 211–220. Horacek, H. J., Ramey, C. T., Campbell, Northwestern University, ... Read Article
KATHRYN MONTGOMERY, PhD Professor Of Medical Humanities And ...
Director of Graduate Studies, Medical Humanities and Bioethics Program Northwestern University Feinberg School of Medicine 750 North Lake Shore Drive - Suite 625 Clinical Choice," Stories and their Limits, ed. HL Nelson, Routledge, 1997. ... Retrieve Here
No comments:
Post a Comment